IAI invests in Tiltan

IAI and Tiltan also have undertaken a strategic cooperation to conduct joint projects for development of various solutions to market in Israel and abroad.

By AVI KRAWITZ
March 6, 2006 07:08
iai logo 88

iai logo 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Israel Aircraft Industries (IAI) said Sunday it has invested NIS 28.75 million to buy a 30 percent share in visualization software provider Tiltan from its parent company Matrix. Under the agreement, which is expected to close in the second quarter, IAI has the option to buy an additional 5% from Matrix for NIS 7.25m. IAI and Tiltan also have undertaken a strategic cooperation to conduct joint projects for development of various solutions to market in Israel and abroad. Motti Gutman, CEO of Matrix, said it had refused higher offers for Tiltan, including taking it public, but felt that "in the long-term, the increase in value for Tiltan with IAI as a strategic partner would be much faster and higher."

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS